Drug Trial Radar · NCT00360529
24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
880
Actual
Start
Jul 2006
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
flibanserinDrug
flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Satisfying Sexual Event Monthly Change From Baseline at Final VisitTime frame: Baseline, Week 24
- Sexual Desire Monthly Change on Electronic Diary From Baseline at Final VisitTime frame: Baseline, Week 24
Locations
54 sites in 2 countries. Site status is shown where the registry gives one.
511.71.01034 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.71.01042 Boehringer Ingelheim Investigational Site
South Birmingham, Alabama
511.71.01016 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.71.01041 Boehringer Ingelheim Investigational Site
La Mesa, California
511.71.01011 Boehringer Ingelheim Investigational Site
San Diego, California
511.71.01027 Boehringer Ingelheim Investigational Site
Westlake Village, California
511.71.01035 Boehringer Ingelheim Investigational Site
Denver, Colorado
511.71.01010 Boehringer Ingelheim Investigational Site
Groton, Connecticut
511.71.01021 Boehringer Ingelheim Investigational Site
New Britain, Connecticut
511.71.01037 Boehringer Ingelheim Investigational Site
Newark, Delaware
511.71.01001 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida
511.71.01032 Boehringer Ingelheim Investigational Site
Clearwater, Florida
511.71.01014 Boehringer Ingelheim Investigational Site
Miami, Florida
511.71.01025 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
511.71.01006 Boehringer Ingelheim Investigational Site
Plantation, Florida
511.71.01015 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
511.71.01038 Boehringer Ingelheim Investigational Site
Marietta, Georgia
511.71.01036 Boehringer Ingelheim Investigational Site
Chicago, Illinois
511.71.01029 Boehringer Ingelheim Investigational Site
Evansville, Indiana
511.71.01028 Boehringer Ingelheim Investigational Site
Renton, Indiana
511.71.01024 Boehringer Ingelheim Investigational Site
New Orlean, Louisiana
511.71.01040 Boehringer Ingelheim Investigational Site
Towson, Maryland
511.71.01045 Boehringer Ingelheim Investigational Site
Brighton, Massachusetts
511.71.01005 Boehringer Ingelheim Investigational Site
St Louis, Missouri
511.71.01030 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
511.71.01007 Boehringer Ingelheim Investigational Site
Rochester, New York
511.71.01012 Boehringer Ingelheim Investigational Site
The Bronx, New York
511.71.01023 Boehringer Ingelheim Investigational Site
New Bern, North Carolina
511.71.01002 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
511.71.01044 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
511.71.01026 Boehringer Ingelheim Investigational Site
Columbus, Ohio
511.71.01039 Boehringer Ingelheim Investigational Site
Edmond, Oklahoma
511.71.01003 Boehringer Ingelheim Investigational Site
Danville, Pennsylvania
511.71.01033 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
511.71.01031 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
511.71.01022 Boehringer Ingelheim Investigational Site
Mt. Pleasant, South Carolina
511.71.01020 Boehringer Ingelheim Investigational Site
Germantown, Tennessee
511.71.01017 Boehringer Ingelheim Investigational Site
San Antonio, Texas
511.71.01018 Boehringer Ingelheim Investigational Site
San Antonio, Texas
511.71.01008 Boehringer Ingelheim Investigational Site
Huntington, West Virginia
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.